Skip to content
Markets News
Stocks1 min read

FDA Clears Roche’s Gazyva for Primary Membranous Nephropathy

Makkler Newsroom
November 16, 2026 · Based on reporting by GlobeNewswire

The approval makes Gazyva the first FDA-approved treatment for the kidney disease, based on a phase III trial against tacrolimus.

Key takeaways

  • Gazyva was approved for adults with primary membranous nephropathy at risk of disease progression.
  • Complete proteinuria remission at two years was 36.1% with Gazyva and 5.7% with tacrolimus.

The FDA approved Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy at risk of disease progression. Roche said it is the first treatment approved by the agency for the condition.

The decision was based on the phase III MAJESTY trial. At two years, 36.1% of patients receiving Gazyva achieved complete remission of proteinuria, compared with 5.7% of those receiving tacrolimus.

The trial also found higher overall remission at week 104 with Gazyva than with tacrolimus, at 50% versus 12.9%. Roche said the drug’s safety results matched its established profile, with no new safety signals identified.

Topics
ROROG.SW
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.